General Information of Drug (ID: DMPLQ1V)

Drug Name
IFX-1 Drug Info
Synonyms IFX-1 mab
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [1]
Hidradenitis suppurativa ED92.0 Phase 2 [2]
Therapeutic Class
Antiviral Agents
Cross-matching ID
PubChem CID
137254326
TTD Drug ID
DMPLQ1V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Complement C5 (CO5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ravulizumab DMSWNJF Paroxysmal nocturnal haemoglobinuria 3A21.0 Approved [4]
Zilucoplan DM9Z4N5 Generalized myasthenia gravis 8C60 Approved [5]
Pozelimab DMTE8DC Large B Cell Lymphoma Approved [6]
Avacincaptad pegol DM1Z3Z2 Geographic atrophy 9B75 Approved [7]
SKY59 DMWOF1E Haemolytic uraemic syndrome 3A21.2 Phase 3 [8]
SB12 DMME6GJ Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [9]
Zimura DM09TVB Macular degeneration 9B78.3 Phase 3 [10]
ABP959 DMDXE4I Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [11]
Coversin DMMEAOL Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [12]
Nomacopan DML6E6G Bullous pemphigoid EB41.0 Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN complement C5 alpha (C5A) TTRJ91Q CO5_HUMAN (678-1676) Inhibitor [3]
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04333420) Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.
7 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217225
8 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920.
9 Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729.
10 C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.
11 A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ?) in healthy male subjects. Eur J Haematol. 2020 Jul;105(1):66-74.
12 Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258.
13 Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022 Jun 1;158(6):641-649.